We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


  Silver Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Various Serum Vitamin D Biomarkers Compared for Sarcopenia

By LabMedica International staff writers
Posted on 25 Aug 2021
Print article
Image: The Agilent 1260 HPLC system (Photo courtesy of Agilent Technologies)
Image: The Agilent 1260 HPLC system (Photo courtesy of Agilent Technologies)
Sarcopenia is an age-related clinical condition characterized by a gradual and generalized loss of skeletal muscle mass with a decrease in strength and physical capacity. It is considered to be one of the risk factors for adverse events in older people, including delirium, disability, institutionalization, and even death.

Vitamin D deficiency is common among older people around the world. Older people are particularly prone to the development of vitamin D insufficiency or deficiency for following reasons: a reduced cutaneous synthesis in the skin, decreased daily sun exposure, and chronic diseases of organs related to vitamin D metabolism.

Clinical Laboratorians at the Gyeongsang National University College of Medicine (Jinju, Korea) and their medical colleagues collected data from May 2018 to December 2019 on a total of 83 hip fracture (HF) surgery patients: 36 with sarcopenia and 47 non-sarcopenia patients, who were included in the analysis. The age of patients was 74.1 ± 12.3 years in the sarcopenia group and 70.7 ± 10.0 years in the non-sarcopenia group. The male-to-female ratio was 0.59 in the sarcopenia group and 0.33 in the non-sarcopenia group.

Measurements of bioavailable 25(OH)D, 24,25-dihydroxyvitamin D (24,25(OH)2D) and total 25-hydroxy vitamin D (25(OH)D) were made using solid-phase extraction (SPE) and subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS). The LC-MS/MS system consisted of an Agilent 1260 HPLC system with an Agilent 6460 triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA, USA).

Vitamin D binding protein (VDBP) concentration was measured using an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN., USA). For GC gene genotyping, genomic DNA was isolated from peripheral blood leukocytes and performed using a TaqMan SNP Genotyping Assay and an ABI ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).

The investigators reported that bioavailable 25(OH)D levels were significantly decreased in the sarcopenia group compared with the non-sarcopenia group. Results of ROC analysis for the diagnosis of sarcopenia using serum level of bioavailable of 25(OH)D revealed that the cutoff point for bioavailable 25(OH)D was 1.70 ng/mL (AUC = 0.649). In the group with a bioavailable 25(OH)D less than 1.70 ng/mL, the incidence of sarcopenia increased by 3.3 times. Among laboratory test results, serum levels of albumin, calcium, alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (AST) were not significantly different either between the two groups (sarcopenia versus non-sarcopenia). However, parathyroid hormone (PTH) was significantly higher in the non-sarcopenia group than in the sarcopenia group.

The authors concluded that among various serum vitamin D biomarkers, bioavailable 25(OH)D was associated with sarcopenia. Thus, bioavailable vitamin D might be used as an auxiliary marker for assessing the risk of sarcopenia. The study was published on August 5, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Gyeongsang National University College of Medicine
Agilent Technologies
R&D Systems
Applied Biosystems

Gold Supplier
Fully Automated ELISA Workstation
EUROLabWorkstation ELISA
Cytology Sample Processor
SDSCP9000 CytoPath Processor
Tips, Pasteur Pipettes and Serological Pipettes
PROMED Tips, Pasteur Pipettes and Serological Pipettes
Cancer Panel

Print article


Molecular Diagnostics

view channel
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)

Biomarker Predicts Potential Benefit of Checkpoint Inhibitor Therapy for Brain Cancer Patients

A phosphorylated form of ERK (extracellular signal-regulated kinase) protein has been identified as a biomarker that may be used to predict which brain cancer patients might benefit from checkpoint inhibitor... Read more


view channel
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)

Monocyte Distribution Width Predicts Sepsis in Critically Ill Patients

Sepsis has been reported as a major cause of increased morbidity, length of stay and mortality among patients hospitalized in Intensive Care Units (ICUs) for any cause. The survival of patients developing... Read more


view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more


view channel
Image: Clinical metagenomics (CMg) using nanopore sequencing (Photo courtesy of Oxford Nanopore Technologies)

Same Day Test Identifies Secondary Infections in COVID-19 Patients

The intensive care unit (ICU) is a dynamic environment with frequent staff-patient contact for invasive monitoring, interventions and personal care that together introduce the risk of secondary or nosocomial... Read more


view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population

The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.